INBS · Intelligent Bio Solutions Inc.

On March 18, 2026, the Issuer granted the reporting person 21,350 restricted shares of Common Stock under the 2019 Plan. The awarded shares are subject to joint performance-based and time-based vesting requirements and are subject to forfeiture until vested.

On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis.

On March 18, 2026, the Issuer granted the reporting person 5,000 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan. The awarded shares are subject to time-based vesting after 12 months and are subject to forfeiture until vested.

On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis.

On March 18, 2026, the Issuer granted the reporting person 9,150 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan ("2019 Plan"). The awarded shares are subject to time-based vesting after 48 months and are subject to forfeiture until vested.

On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis.

On March 18, 2026, the Issuer granted the reporting person 9,150 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan ("2019 Plan"). The awarded shares are subject to time-based vesting after 48 months and are subject to forfeiture until vested.

On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis.

On March 18, 2026, the Issuer granted the reporting person 21,350 restricted shares of Common Stock under the 2019 Plan. The awarded shares are subject to joint performance-based and time-based vesting requirements and are subject to forfeiture until vested.

On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis.

On March 18, 2026, the Issuer granted the reporting person 5,000 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan. The awarded shares are subject to time-based vesting after 12 months and are subject to forfeiture until vested.

On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis.

On March 18, 2026, the Issuer granted the reporting person 5,000 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan. The awarded shares are subject to time-based vesting after 12 months and are subject to forfeiture until vested.

On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis.

On March 18, 2026, the Issuer granted the reporting person 5,000 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan. The awarded shares are subject to time-based vesting after 12 months and are subject to forfeiture until vested.

On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis.

On September 25, 2024, the Issuer granted the reporting person 34,500 shares of the Issuer's common stock pursuant under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan.

The number of reported securities has been adjusted to correct a clerical error that had previously caused the reporting person's holding to be underreported by 1 share.

On September 25, 2024, the Issuer granted the reporting person 40,000 shares of the Issuer's common stock pursuant under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan.

The number of reported securities has been adjusted to (i) reflect a 1-for-12 reverse stock split effected on January 26, 2024, and (ii) correct a clerical error that had previously caused the reporting person's holding to be underreported by 59 shares.

The Series F Warrants have an exercise price is $6.60 per share (after Reverse Stock Split related adjustments) and are also exercisable pursuant to an alternate cashless exercise formula set forth in the warrant. The Series F Warrants in the reported transaction were exercised pursuant to the alternate cashless exercise formula for an equal number of shares of common stock on a one-for-one basis, without payment of additional consideration therefore.

The number of reported securities has been adjusted in order to reflect a 1-for-12 reverse stock split effected on January 26, 2024 (the "Reverse Stock Split").

The Series F Warrants became exercisable on November 17, 2023, the date the Issuer's stockholders approved, for purposes of complying with Nasdaq Listing Rules 5635(c) and (d), the issuance of the shares underlying the Series F Warrants.

These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a director.

The Series F Warrants have an exercise price is $6.60 per share (after Reverse Stock Split related adjustments) and are also exercisable pursuant to an alternate cashless exercise formula set forth in the warrant. The Series F Warrants in the reported transaction were exercised pursuant to the alternate cashless exercise formula for an equal number of shares of common stock on a one-for-one basis, without payment of additional consideration therefore.

The number of reported securities has been adjusted in order to reflect a 1-for-12 reverse stock split effected on January 26, 2024 (the "Reverse Stock Split").

These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a director.

The exercise price of the Series F Warrants is $0.55 per share. However,under the alternate cashless exercise option of the Series F Warrants, the holder of the Series F Warrant (beginning on the date the Warrant Stockholder Approval is effective), has the right to receive an aggregate number of shares of Common Stock on a one-for-one basis (subject to adjustment).

The reported securities are included within 9,090 INBS Class A Units purchased by the reporting person for $0.55 per Unit. Each Unit consists of one share of the common stock, one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series E Warrants"), and one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series F Warrants"). The Warrants will be exercisable beginning on the effective date of such stockholder approvals as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) to permit the exercise of the Warrants ("Warrant Stockholder Approval").

The exercise price of the Series E Warrants is $0.55 per share. However, under the one-time reset provision of the Series E Warrants, the exercise price of the Series E Warrants will reset to a price equal to the lesser of (i) the then exercise price and (ii) 90% of the five-day volume weighted average price for the five trading days immediately following the date the Company effects a reverse stock split.

The reported securities are included within 9,090 INBS Class A Units purchased by the reporting person for $0.55 per Unit. Each Unit consists of one share of the common stock, one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series E Warrants"), and one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series F Warrants"). The Warrants will be exercisable beginning on the effective date of such stockholder approvals as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) to permit the exercise of the Warrants ("Warrant Stockholder Approval").

The reported securities are included within 9,090 INBS Class A Units purchased by the reporting person for $0.55 per Unit. Each Unit consists of one share of the common stock, one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series E Warrants"), and one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series F Warrants"). The Warrants will be exercisable beginning on the effective date of such stockholder approvals as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) to permit the exercise of the Warrants ("Warrant Stockholder Approval").

On February 9, 2023, the Issuer effected a 1-for-20 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split.

On February 9, 2023, the Issuer effected a 1-for-20 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split.

On February 9, 2023, the Issuer effected a 1-for-20 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split.

On February 9, 2023, the Issuer effected a 1-for-20 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split. This Form 4 also corrects the number of securities held directly and indirectly by Mr. Sakiris. Prior to the Reverse Split, each share of Series D Convertible Preferred Stock (the "Preferred Stock") was convertible into 3 shares of common stock. Following the Reverse Split, each share of Preferred Stock was convertible into 0.15 shares of common stock.

Following the Trigger Date (defined below), each share of Preferred Stock was convertible at any time at the option of the holder and without payment of further consideration. The Preferred Stock has no expiration date. The term "Trigger Date" means the earlier to occur of (i) the date that the last of (a) the shareholders approve conversion of the Preferred Stock or (b) the shareholders approve a reverse split of the Issuer's common stock; or (ii) the date which is 60 days following the date on which the common stock is no longer listed on the Nasdaq, the NYSE or the NYSE American. The Issuer's stockholders approved the conversion of the Preferred Stock at a meeting of stockholders on May 8, 2023, and effective as of May 10, 2023, all shares Preferred Stock were converted into common stock.

On December 22, 2022, Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, purchased 15,993 units from the Issuer in a private placement. Each unit consists of one share of Series D Convertible Preferred Stock (valued at $0.87 each (pre- Reverse Split)) and three common stock purchase warrants (collectively valued at $0.35(pre- Reverse Split), or $0.1267 each (pre- Reverse Split)). The purchase price of each unit was $1.25 per unit (pre- Reverse Split).

These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a director.

Following the Trigger Date (defined below), each share of Preferred Stock was convertible at any time at the option of the holder and without payment of further consideration. The Preferred Stock has no expiration date. The term "Trigger Date" means the earlier to occur of (i) the date that the last of (a) the shareholders approve conversion of the Preferred Stock or (b) the shareholders approve a reverse split of the Issuer's common stock; or (ii) the date which is 60 days following the date on which the common stock is no longer listed on the Nasdaq, the NYSE or the NYSE American. The Issuer's stockholders approved the conversion of the Preferred Stock at a meeting of stockholders on May 8, 2023, and effective as of May 10, 2023, all shares Preferred Stock were converted into common stock.

On February 9, 2023, the Issuer effected a 1-for-20 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split. This Form 4 also corrects the number of securities held directly and indirectly by Mr. Sakiris. Prior to the Reverse Split, each share of Series D Convertible Preferred Stock (the "Preferred Stock") was convertible into 3 shares of common stock. Following the Reverse Split, each share of Preferred Stock was convertible into 0.15 shares of common stock.

On December 22, 2022, Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, purchased 15,993 units from the Issuer in a private placement. Each unit consists of one share of Series D Convertible Preferred Stock (valued at $0.87 each (pre- Reverse Split)) and three common stock purchase warrants (collectively valued at $0.35(pre- Reverse Split), or $0.1267 each (pre- Reverse Split)). The purchase price of each unit was $1.25 per unit (pre- Reverse Split).

These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a director.

Subject to adjustment.

On December 22, 2022, Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, purchased 15,993 units from the Issuer in a private placement. Each unit consists of one share of Series D Convertible Preferred Stock (valued at $0.87 each) and three common stock purchase warrants (collectively valued at $0.35, or $0.1267 each). The purchase price of each unit was $1.25 per unit.

These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a Director.

The Series D Convertible Preferred Stock is initially convertible into three shares of common stock of the Issuer. The conversion ratio is subject to adjustment. Following the Trigger Date (defined below), each share of Series D Convertible Preferred Stock is convertible at any time at the option of the holder and without payment of further consideration. The Series D Convertible Preferred Stock has no expiration date. As used herein, "Trigger Date" means the earlier to occur of (i) the date that the last of (a) the Issuer's shareholders approve the conversion of the Series D Convertible Preferred Stock or (b) the Issuer's shareholders approve a reverse split of the Issuers's common stock, or (ii) the date which is 60 days following the date on which the Common Stock is no longer listed on the Nasdaq Stock Market, the New York Stock Exchange or the NYSE American.

On December 22, 2022, Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, purchased 15,993 units from the Issuer in a private placement. Each unit consists of one share of Series D Convertible Preferred Stock (valued at $0.87 each) and three common stock purchase warrants (collectively valued at $0.35, or $0.1267 each). The purchase price of each unit was $1.25 per unit.

These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a Director.

Amount reflects corrected number of shares owned. The Form 4 filed on May 21, 2021, inadvertently omitted 3,000 shares and did not reflect the correct number of shares owned.